Drug General Information
Drug ID	D02OTK
Former ID	DNCL001654
Drug Name	CH-4051
Indication	Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]		Phase 2	[523026]
Company	Chelsea Therapeutics
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	DHFR	Target Info	Inhibitor	[531111]
KEGG Pathway	One carbon pool by folate
	Folate biosynthesis
	Metabolic pathways
PANTHER Pathway	Tetrahydrofolate biosynthesis
	Formyltetrahydroformate biosynthesis
Pathway Interaction Database	E2F transcription factor network
PathWhiz Pathway	Folate Metabolism
	Pterine Biosynthesis
Reactome	E2F mediated regulation of DNA replication
	Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
	Metabolism of folate and pterines
	G1/S-Specific Transcription
WikiPathways	Nucleotide Metabolism
	Trans-sulfuration and one carbon metabolism
	Retinoblastoma (RB) in Cancer
	One Carbon Metabolism
	Metabolism of water-soluble vitamins and cofactors
	Metabolism of nitric oxide
	Folate Metabolism
	Fluoropyrimidine Activity
References
Ref 523026	ClinicalTrials.gov (NCT01116141) A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA). U.S. National Institutes of Health.
Ref 531111	CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.